Actor Lee Jae-wook vows legal action against malicious rumors
Police raid striking doctors' homes, offices, after deadline passes on return-to-work order
Yoon touts improved Japan ties on Independence Movement Day as gateway to 'new world'
S. Korea, US voice 'deep concern' over NK's definition of S. Korea as 'hostile' country
S.Coups of Seventeen gets military exemption due to knee injury
Korean stocks benefit from Zuckerberg's Seoul visit
Most doctors refuse to end strike on last day of ultimatum
Vote on bill to probe first lady lays bare Democratic Party split
Address by President Yoon Suk Yeol on the 105th March 1st Independence Movement Day
Cooperation among N. Korea, Russia, China, Iran raises possibility of 'simultaneous conflicts': US general
SK Biopharmaceuticals acquires 60 percent stake in Proteovant Therapeutics at W62bBy Yu Ji-soo
Published : June 30, 2023 - 16:42
SK Group’s pharmaceutical arm, SK Biopharmaceuticals, said Friday that it has decided to acquire a 60 percent stake, or 40 million shares, in US biotech company Proteovant Therapeutics for 62 billion won ($47 million).
This deal size is equivalent to 19.6 percent of the Korean company’s total equity capital.
Established in New York in 2021, Proteovant Sciences is a 60:40 joint venture between Swiss biotech company Roivant Sciences and SK Group.
SK Biopharmaceuticals expects that the transaction will help the firm to secure targeted protein degradation technology to treat patients with debilitating diseases like cancer.
Targeted protein degradation refers to an emerging drug discovery process that can potentially be used to treat infectious diseases. Essentially, the process selectively eradicates disease-causing proteins from cells by using small molecules called degraders or proteolysis-targeting chimeras to redirect the cell's natural protein degradation machinery to target those problem proteins.
Lee Dong-hoon, the current CEO of SK Biopharmaceuticals, was directly involved in the establishment of Proteovant Therapeutics during his tenure as the head of SK Bio Investment Center.
Opposition leader retains ticket to his constituency
Car camping: How solo female campers enjoy outdoors
Tensions loom as doctors plan mass rally in deepening clash over med school quota